This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Synopsys-Ansys merger approved by China's SAMR with conditions

( July 14, 2025, 07:16 GMT | Official Statement) -- MLex Summary: China's State Administration for Market Regulation today conditionally approved US semiconductor software company Synopsys’ planned acquisition of rival Ansys. As part of the remedy package, the regulator has required Synopsys to divest its entire optical and photonic-device simulation business, and Ansys to divest its power consumption-analysis software operations. The regulator also imposed behavioral remedies for a period of 10 years, requiring the merging companies to honor all existing customer contracts and refrain from bundling or tying their respective products. They must also provide continued support for industry standard formats in relevant EDA products, maintain existing interoperability agreements, enter into interoperability agreements with third-party EDA vendors upon written support from Chinese customers, the regulator said in a statement posted on its website. The statement follows and the remedy plan is attached:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login